Table.
Outcomes for women with opioid use disorder
|
Number of participants (n=13) |
In-person (before virtual-only meetings) | Virtual-only | Combined (after virtual-only meetings) | P value |
|---|---|---|---|---|
| Period | Feb. 19–March 11 | April 1–May 26 | May 27–June 25 | |
| Number of group therapy sessions offered over defined period | 4 | 8 | 5 | |
| Percentage of group therapy sessions attended | 67±21.4 | 21±18.7 | 68±22.4 | <.001a |
| Positive UDS tests for illicit substances | 9 (21) | 8 (13) | 2 (5) | .12 |
| ED or triage visitsb | 1 (8) | 4 (30) | 1 (8) | .17 |
| Reported assaultsb | 0 (0) | 2 (15) | 0 (0) | .08 |
| Overdosesb | 0 (0) | 1 (8) | 0 (0) | .39 |
| Uptitration of MAT dosage during defined periodb | 0 (0) | 5 (38) | 1 (8) | .02a |
| Average number of craving questionnaires completed per participant | 2.8±0.8 | 3.2±1.2 | 3.4±0.9 | .47 |
| Total craving scores | 3.6 [3–5] | 4.3 [3–8.5] | 3.7 [3–5.5] | .15 |
Data are presented as number (percentage), mean±standard deviation, or median [interquartile range], as applicable.
ED, emergency department, MAT, medication-assisted therapy; UDS, urine drug screen.
McKiever. Telehealth transition for OUD pregnancies during the COVID-19 pandemic. Am J Obstet Gynecol 2020.
a
Statistically significant (P<.05)
b
The number of ED or triage visits, reported assaults, and uptitration of MAT dosage visits were only counted once per participant in each specific period.